RxSight opened lower at $5.25, compared with its previous close of $5.28. In the last trading session, the stock traded between $5.04 and $5.50. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in RxSight is now worth
$ 42.71
Resulting in a loss of
$ 57.29 (57.29%)
Invest with $1
Note: Past profits do not guarantee future returns.
Piper Sandler lowered the price target for RxSight from $10 to $8. Analyst Adam Maeder maintained a Neutral rating on the stock. The price target reduction represents a 20% decrease from the prior level.
8 days ago
4Nov
Wells Fargo maintains Equal-Weight on RxSight, cuts target to $6
Wells Fargo lowered RxSight's price target from $9 to $6. Analyst Larry Biegelsen maintained an Equal-Weight rating. The rating action indicates a neutral stance with reduced valuation expectations.
8 days ago
4Nov
Needham maintains Buy on RxSight, cuts price target to $7
Needham maintains a Buy rating on RxSight. Price target lowered from $11 to $7. Analyst David Saxon authored the rating update.
8 days ago
21Oct
RxSight Inc. Q3FY26 Results: Earnings call set for November 3, 2026
RxSight Inc. will report Q3 2026 financial results on November 3, 2026. Earnings conference call scheduled for 4:30 pm Eastern Time. Company specializes in adjustable intraocular lens technology for cataract surgery.
23 days ago
27Aug
RxSight to present at Wells Fargo Healthcare Conference in September
RxSight management to present at Wells Fargo Healthcare Conference. Session scheduled for September 9, 2026, at 9:30 am ET. Event held in Boston with live webcast available online. Company offers unique light-adjustable intraocular lens technology.
2mo ago
27Jul
RxSight grants Aziz Mottiwala 2.3M RSUs, 571K options
RxSight, Inc. awarded Aziz Mottiwala, its new President and CEO, 571,286 stock options and 2,312,138 RSUs on July 24, 2026. The options have an exercise price of $5.19 and vest over four years, while the RSUs vest over three years with a heavy back-end loading. The grants comply with Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.
